news
Antibody effector functions are key to combatting COVID-19, finds study
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
List view / Grid view
Immunology
news
COVID-19 vaccine tablet significantly reduces viral load in hamsters
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
news
Researchers dicover novel targets for rheumatoid arthritis therapies
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
news
T cells facilitate chronic lung injury in the elderly after viral infections, finds study
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
news
Pre-existing coronavirus antibodies could protect against new COVID-19 strains
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
news
Children produce a different antibody response to SARS-CoV-2 infection, finds study
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
news
Autoantibodies and over-active neutrophils may be cause of COVID-19 blood clots
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
news
Researchers reveal how allergens may trigger itching
Certain sensory neurons and Substance P are potential drug targets for the development of novel allergy preventions or treatments, according to scientists.
news
SARS-CoV-2 specific antibodies persist for five months in mild cases
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
news
Researchers discover novel cancer immunosuppression mechanism
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
news
Leveraging flow cytometry to explore COVID-19 immune responses
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
video
On-demand webinar: Complete workflow solution from gene-to-protein
23 October 2020 | By
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
article
Treating cytokine storms in COVID-19 patients
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
news
Severe COVID-19 symptoms may not be caused by cytokine storm
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
news
SARS-CoV-2 also uses neuropilin-1 to infect human cells
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.